SOCS1-Derived Peptide for Diabetic Retinopathy Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for diabetic complications, particularly diabetic retinopathy, are ineffective in preventing initial phases and have significant side effects, with no specific therapies available for neurodegenerative diseases of the retina like diabetic retinopathy, macular edema, and glaucoma.

Innovation Solution

A SOCS1-derived peptide, specifically a polypeptide sequence or its variants, is used for topical administration to prevent or treat chronic complications of diabetes and neurodegenerative diseases of the retina, including diabetic retinopathy, by acting as a neuroprotective agent and modulating the JAK/STAT signaling pathway.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments (laser photocoagulation, intravitreal injections) are used for advanced diabetic retinopathy, then disease progression is slowed, but side effects increase and effectiveness decreases

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts and utilizes the specific kinase inhibitory region (amino acids 46-61) of the SOCS1 protein to create a therapeutic peptide. This extracted region specifically targets and inhibits JAK2 kinase activity, which is overactive in diabetic retinopathy, thereby providing targeted therapy that reduces harmful effects while maintaining effectiveness.

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The SOCS1-derived peptide acts as an intermediary molecule that mediates the inhibition between the JAK/STAT signaling pathway and the pathological processes of diabetic retinopathy. By binding to JAK2 kinase, the peptide interferes with the abnormal signaling that leads to retinal damage, effectively blocking the harmful cascade without directly damaging retinal tissue.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Loss of time

If no specific treatment is applied in initial phases of diabetic retinopathy, then neurodegeneration progresses undetected, but early intervention is needed before microvascular lesions are visible

Engineering Contradiction:

Improvedetection timeVSAvoidtreatment availability

Core Design Contradiction:

Loss of timeVSReliability

Solution Approach 1:

The patent enables preliminary action by providing a therapeutic agent that can be administered in the initial phases of diabetic retinopathy, before microvascular lesions become visible. The SOCS1-derived peptide targets the underlying JAK2 kinase hyperactivity that drives neurodegeneration early in the disease process, allowing intervention before irreversible damage occurs.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent replaces mechanical/invasive detection and treatment methods with a molecular-level approach. Instead of waiting for structural changes visible through traditional ophthalmologic examination, the therapy targets molecular signaling abnormalities (JAK2 kinase activity) that occur earlier in the disease process, enabling earlier detection and treatment.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Stability of the object's composition

If current glucose and hypertension control approaches are maintained, then disease progression is stopped, but chronic complications still develop in many cases

Engineering Contradiction:

Improvedisease progression controlVSAvoidprevention of chronic complications

Core Design Contradiction:

Stability of the object's compositionVSReliability

Solution Approach 1:

The patent introduces a new therapeutic parameter - JAK2 kinase inhibition - that complements existing glucose and hypertension control. By targeting the downstream signaling pathway (JAK/STAT) that is independently activated in diabetic retinopathy, the SOCS1-derived peptide provides an additional mechanism to prevent chronic complications that are not fully controlled by metabolic management alone.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The peptide effectively reduces glial activation, apoptosis, and disruption of the blood-retinal barrier, improving retinal function and preventing progression of diabetic retinopathy, while also showing renoprotective and anti-atherosclerotic effects.

Implementation Method 1

Methodology Applied

Scientific EffectJAK/STAT signaling pathway modulation:

Data Source

PatentUS10532082B2SOCS1-derived peptide for use in chronic complications of diabetes

Publication Date: 2020.01.14 AUTONOMOUS UNIVERSITY OF MADRID

AI summary

The present invention relates to a SOCS1-derived peptide for use in chronic complications of diabetes, particularly ocular, renal, nerve and vascular complications, as well as compositions containing same and isolated polynucleotides encoding same. The present invention also relates to the SOCS1-derived peptide for topical use in the treatment and/or prevention of neurodegenerative diseases of the retina, particularly in the early stages of diabetic retinopathy and other diseases of the retina in which neurodegeneration plays an essential role.